dyn101
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04033159)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Dynamin-2ANTISENSE INHIBITOR
DNM2 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04743557 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2021 | Dynacure |
| NCT04033159 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2019 | Dynacure, Radboud University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dynacure | For profit | 2 | 2 | 1 | 2019 |
| Radboud University | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1